Monashee Reduces Stake in Structure Therapeutics Amid Competitive Landscape
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 20 2026
0mins
Source: Fool
- Stake Reduction Details: Monashee Investment Management reduced its holdings in Structure Therapeutics by 175,000 shares in Q1 2026, with an estimated transaction value of $11.98 million, resulting in a $13.24 million decrease in its GPCR position, indicating a cautious outlook on the company's future potential.
- Holding Proportion Analysis: Post-reduction, Monashee's remaining stake accounts for 1.8% of its 13F reportable assets, suggesting a diminished confidence in the company despite its strong performance in clinical testing.
- Market Competition Landscape: The GLP-1 weight loss drug market is highly competitive, and while Structure's oral therapies show promising results in trials, numerous pharmaceutical companies are developing similar products, increasing future uncertainty.
- Investor Strategy Recommendation: Given Monashee's reduction, investors may prefer ETFs that encompass the GLP-1 sector, such as the Roundhill GLP-1 & Weight Loss ETF, to diversify risk and capture market opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GPCR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GPCR
Wall Street analysts forecast GPCR stock price to rise
15 Analyst Rating
15 Buy
0 Hold
0 Sell
Strong Buy
Current: 40.170
Low
65.00
Averages
106.50
High
140.00
Current: 40.170
Low
65.00
Averages
106.50
High
140.00
About GPCR
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Analyst Rating Boost: Truist has initiated coverage on Viking Therapeutics (VKTX) with a ‘Buy’ rating and an $83 price target, indicating a potential upside of 162% from current levels, reflecting strong market confidence in its growth prospects.
- Weight Loss Market Dynamics: Eli Lilly (LLY) saw its stock price climb nearly 25% over the past month, making it the strongest performer among major obesity drug stocks, highlighting investor recognition of its sustained demand for GLP-1 therapies and market leadership.
- Viking's Competitive Edge: Truist emphasized that Viking's VK2735 drug achieved a 14.7% weight loss in just 13 weeks, with patients continuing to lose weight, showcasing its differentiated competitive advantage in the obesity drug market that could attract more patients.
- Lilly's Market Expansion: Lilly recently announced deals worth up to $3.8 billion with three vaccine developers, further expanding its footprint in infectious diseases and long-term healthcare infrastructure, indicating growth potential beyond its obesity drug portfolio.
See More
- Stake Increase: Deep Track Capital disclosed an acquisition of 168,066 shares of Structure Therapeutics in Q1 2026, with an estimated transaction value of $11.50 million, indicating confidence in the company's growth potential.
- Ownership Proportion: Following this purchase, Deep Track's stake in Structure rose to 3.37%, representing a significant position within its $6.12 billion reportable U.S. equity holdings, highlighting the fund's commitment to the company.
- Market Performance: As of last Friday, Structure Therapeutics' shares were priced at $39.19, reflecting a 60% increase over the past year, significantly outperforming the S&P 500's 28% rise, suggesting strong market optimism regarding its future.
- R&D Progress: The company reported a Phase 2 trial for its oral GLP-1 candidate aleniglipron showing up to 16.3% weight loss, with plans to initiate Phase 3 studies in Q3 2026, which could solidify its competitive position in the obesity market if successful.
See More
- Stake Increase: Deep Track Capital acquired an additional 168,066 shares of Structure Therapeutics in Q1 2026, with an estimated transaction value of $11.50 million, indicating confidence in the company's future value creation potential.
- Decline in Position Value: Despite the increase, the quarter-end position value decreased by $79.69 million, reflecting the dual impact of trading activity and stock price fluctuations, highlighting market concerns about the stock's volatility.
- Clinical Advancements: Structure Therapeutics' oral GLP-1 candidate aleniglipron demonstrated a weight loss of up to 16.3% in Phase 2 trials, potentially comparable to injectable therapies, enhancing its competitiveness in the obesity market.
- Strong Financial Position: The company ended the quarter with approximately $1.5 billion in cash and short-term investments, sufficient to support operations through the end of 2028, showcasing a robust financial foundation for R&D and market expansion.
See More
- Stake Reduction Details: Monashee Investment Management reduced its holdings in Structure Therapeutics by 175,000 shares in Q1 2026, with an estimated transaction value of $11.98 million, resulting in a $13.24 million decrease in its GPCR position, indicating a cautious outlook on the company's future potential.
- Holding Proportion Analysis: Post-reduction, Monashee's remaining stake accounts for 1.8% of its 13F reportable assets, suggesting a diminished confidence in the company despite its strong performance in clinical testing.
- Market Competition Landscape: The GLP-1 weight loss drug market is highly competitive, and while Structure's oral therapies show promising results in trials, numerous pharmaceutical companies are developing similar products, increasing future uncertainty.
- Investor Strategy Recommendation: Given Monashee's reduction, investors may prefer ETFs that encompass the GLP-1 sector, such as the Roundhill GLP-1 & Weight Loss ETF, to diversify risk and capture market opportunities.
See More
- Share Reduction Transaction: HighVista Strategies sold 69,092 shares of Structure Therapeutics in Q1 2026, with an estimated transaction value of $4.73 million, indicating a potential shift in confidence regarding the company.
- Decline in Position Value: This sale resulted in a $7.45 million decrease in HighVista's position value in Structure Therapeutics, highlighting the impact of market price fluctuations on its investment portfolio.
- Strong Company Performance: As of May 14, 2026, Structure Therapeutics' shares were priced at $39.84, reflecting a 60% increase over the past year, significantly outperforming the S&P 500's 25% gain, indicating strong market recognition of its future potential.
- Positive Clinical Progress: Structure Therapeutics reported promising Phase 2 data for its oral obesity candidate aleniglipron, showing up to 16.3% placebo-adjusted weight loss at 44 weeks, underscoring its competitive edge in the GLP-1 therapy market.
See More
- Complete Exit: ACT Capital Management sold all 38,500 shares of Structure Therapeutics in Q1 2026, with an estimated trade value of $2.63 million, indicating a full exit that reflects a cautious stance amid biotech market volatility.
- Net Position Change: The transaction resulted in a $2.68 million decrease in ACT's net position, suggesting that after a significant price increase, management opted to lock in profits at a high point to mitigate potential market risks.
- Strong Company Performance: As of May 7, 2026, Structure Therapeutics shares were priced at $39.15, up 47% over the past year, outperforming the S&P 500 by 17 percentage points, highlighting its robust growth potential in chronic disease treatment.
- Strong Financial Position: Structure ended the quarter with approximately $1.5 billion in cash and short-term investments, which is expected to fund operations through the end of 2028, enhancing its competitive edge in future product development and commercialization.
See More











